title: [Renin-angiotensin-aldosterone system inhibitors and electrolyte disturbances].
abstract: Recent numerous clinical studies have suggested that the renin-angiotensin-aldosterone system (RAAS) inhibitors have beneficial effects on hypertension, cardiovascular and chronic kidney diseases (CKD). Electrolyte disorder, especially hyperkalemia, is observed after the administration of RAAS inhibitors. This review focuses on the prevalence and severity of hyperkalemia with the use of RAAS inhibitors. Clinical evidences suggest that hypertensive patients with heart failure and CKD, and patients with combination treatment of RAAS inhibition are at higher risk of hyperkalemia, and serum potassium levels should be carefully monitored.
authors.affiliation: Department of Internal Medicine, School of Medicine, Teikyo University.
authors.forename: Hideki
authors.initials: H
authors.lastname: Kato
authors.forename: Kana
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Shunya
authors.initials: S
authors.lastname: Uchida
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006947:Hyperkalemia / Q000188:drug therapy* / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D012084:Renin-Angiotensin System / Q000187:drug effects; D014883:Water-Electrolyte Imbalance
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors